UBS AM
TRVI icon

UBS AM’s Trevi Therapeutics TRVI Stock Holding History

UBS AM’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.42M Buy
183,225
+29,057
+19% +$423K ﹤0.01% 1805
2026
Q1 		$1.84M Buy
154,168
+13,435
+10% +$150K ﹤0.01% 2077
2025
Q4 		$1.76M Buy
140,733
+24,256
+21% +$280K ﹤0.01% 1938
2025
Q3 		$1.07M Buy
+116,477
New +$873K ﹤0.01% 1983

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

UBS AM's TRVI Position: Q2 2026 in Review

UBS AM increased its Trevi Therapeutics (TRVI) stake by 19% in Q2 2026, buying an estimated $423K and bringing the position to 183,225 shares worth $3.42M. The position accounts for ﹤0.01% of the portfolio, ranked #1805.

UBS AM first reported a position in TRVI in Q3 2025 and has held it in 4 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • UBS AM held 183,225 shares of Trevi Therapeutics worth $3.42M as of Q2 2026.
  • UBS AM bought 29,057 Trevi Therapeutics shares in Q2 2026, an estimated $423K.
  • Trevi Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1805 holding.
  • UBS AM first reported a position in Trevi Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.